|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
13
|
|
pubmed:dateCreated |
2005-7-7
|
|
pubmed:abstractText |
Oxaliplatin-5-fluorouracil combinations have increased responses in first-line therapy up to 40% in advanced colorectal cancer. Unfortunately, those patients who will respond are unknown and initially sensitive patients become rapidly resistant to current therapies. FAS (CD95) and FAS ligand (FASL; CD95L) have been implicated in chemosensitivity through leading to apoptosis in response to DNA-damaging drugs. Whereas the proapoptotic role of FAS and FASL is well characterized, the function of their soluble forms as predictors of chemosensitivity remains unknown.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, CD95,
http://linkedlifedata.com/resource/pubmed/chemical/FASLG protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Fas Ligand Protein,
http://linkedlifedata.com/resource/pubmed/chemical/Fluorouracil,
http://linkedlifedata.com/resource/pubmed/chemical/Membrane Glycoproteins,
http://linkedlifedata.com/resource/pubmed/chemical/Organoplatinum Compounds,
http://linkedlifedata.com/resource/pubmed/chemical/Tumor Markers, Biological,
http://linkedlifedata.com/resource/pubmed/chemical/Tumor Necrosis Factors,
http://linkedlifedata.com/resource/pubmed/chemical/oxaliplatin
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jul
|
|
pubmed:issn |
1078-0432
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
1
|
|
pubmed:volume |
11
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
4770-4
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:16000573-Adult,
pubmed-meshheading:16000573-Aged,
pubmed-meshheading:16000573-Aged, 80 and over,
pubmed-meshheading:16000573-Antigens, CD95,
pubmed-meshheading:16000573-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:16000573-Colorectal Neoplasms,
pubmed-meshheading:16000573-Drug Resistance, Neoplasm,
pubmed-meshheading:16000573-Enzyme-Linked Immunosorbent Assay,
pubmed-meshheading:16000573-Fas Ligand Protein,
pubmed-meshheading:16000573-Female,
pubmed-meshheading:16000573-Fluorouracil,
pubmed-meshheading:16000573-Humans,
pubmed-meshheading:16000573-Male,
pubmed-meshheading:16000573-Membrane Glycoproteins,
pubmed-meshheading:16000573-Middle Aged,
pubmed-meshheading:16000573-Multivariate Analysis,
pubmed-meshheading:16000573-Organoplatinum Compounds,
pubmed-meshheading:16000573-Predictive Value of Tests,
pubmed-meshheading:16000573-Regression Analysis,
pubmed-meshheading:16000573-Tomography, X-Ray Computed,
pubmed-meshheading:16000573-Treatment Outcome,
pubmed-meshheading:16000573-Tumor Markers, Biological,
pubmed-meshheading:16000573-Tumor Necrosis Factors
|
|
pubmed:year |
2005
|
|
pubmed:articleTitle |
FAS/FAS ligand ratio: a marker of oxaliplatin-based intrinsic and acquired resistance in advanced colorectal cancer.
|
|
pubmed:affiliation |
Medical Oncology, Institut Malalties Hemato-Oncologiques, Gastroenterology Department, Hospital Clinic Barcelona, Institut d'Investigacions Bimédiques August Pi i Sunyer, University of Barcelona, Barcelona, Spain.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
